Clinical trials: Hair Loss/Baldness
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer